
10 Worst Drug Launches | MD Magazine



Find authenticated court documents without watermarks at docketalarm.com.

10 Worst Drug Launches | MD Magazine

3. Zaltrap

Company: Sanofi Condition/Disease: colorectal cancer Sales: 7 million euros in the third quarter of 2012 Price: \$9,600 a month

Sanofi had a second drug in the top 10, so it's familiar with development risk. The problem with Zaltrap was that it was quite expensive. Providers didn't like that there were less expensive alternatives that were just as good.

2. Provenge

Company: Dendreon Condition/Disease: prostate cancer Sales: \$228 million in 2011 Price: \$93,000 for the treatment

While Provenge's sales weren't bad, they fell far short of Dendreon's forecast of \$350 million. Plus, Johnson & Johnson's Zytiga has become a popular alternative. Although, Zytiga is approved for use after chemotherapy fails, physicians have been prescribing it for off-label use in earlier stages of the disease, causing J&J's drug to increase market share, while Provenge's stagnated. Lastly, oncology drugs always have large price tags and physicians were concerned about reimbursements.

1. Makena

Company: K-V Pharmaceuticals Condition/Disease: preventing premature birth Sales: \$5.1 million in revenue for the final quarter of 2011 Price: \$1,500 a dose

Overall the cost for a full course of treatment is \$30,000, yet a string of compounding pharmacies were already making this therapy for a lot cheaper — just \$10 to \$20 a dose.

To see the full list and more about the drugs, click here.

Comment (0)

DOCKET

Δ



	CONFERENCES >	CONTRIBUTORS >	MJH Associates >	Resources	
	VIDEOS > Peer Exchange	JOURNALS > Physician's money digest >	AJMC CURE HRA	About Us Advertise Careers	

2/9/2016

10 Worst Drug Launches | MD Magazine

Insights	Personal Finance	ONCLive	Contact Us
Resources	Investing	OTCGuide	Press Release
Practice Brief	Retirement	Pharmacy Times	Privacy Policy
Affordable Care Act	Practice Management	RareDR	Staff
Military Medicine	Lifestyle	Specialty Pharmacy Times	Terms & Conditions
	Columns	Targeted Oncology	Copyright MD Magazine 2006-
			2015 Intellisphere, LLC. All
			Rights Reserved.